UNASSIGNED: Nodular lymphocyte predominant @entity978 (nLPHL) comprises approximately 10-12% of all childhood @entity978 . As the majority have low stage disease recent years have seen a de-escalation of treatment intensity to avoid treatment-related morbidity. This report evaluates treatment outcome in @entity1 with histopathological variants of nLPHL after therapy de-escalation. Biopsies from 60 @entity1 were reviewed and histology categorized as typical (n  =  47; 78%) or variant nLPHL (n  =  13; 22%). Furthermore, presence of immunoglobulin D (IgD) expression by the lymphocyte predominant (LP) cells was assessed in 41 @entity1 . Treatment outcomes were compared according to treatment received and histopathology of nLPHL. Compared to typical nLPHL, @entity1 with variant nLPHL had higher stage disease at diagnosis (stage III: 3/13; 23% vs. 3/47; 6%, P  =  0  11), lower complete response rates (6/13; 46% vs. 38/47; 81%, P  =  0  029) and higher relapse rates (2/13; 15% vs. 2/47; 4%, P  =  0  20). Additionally, IgD expression by LP cells was associated with poorer treatment response and was more commonly seen in @entity1 with variant nLPHL. (11/13; 85% vs. 15/28; 54%, P  =  0  08). Variant histology appears to be indicative of a poorer prognosis in @entity1 with early stage disease, and may be an important factor to take into account when moving towards reduced intensity treatment for nLPHL.

Childhood and Adolescent nodular lymphocyte predominant XXXX - A review of clinical outcome based on the histological variants.

@entity1 :: ('9606', 'Species') :: ['patients', 'children'] @entity978 :: ('MESH:D006689', 'Disease') :: ['Hodgkin lymphoma']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin lymphoma']
